TY  - GEN
AU  - Phillips,G L
AU  - Meisenberg,B R
AU  - Reece,D E
AU  - Adams,V R
AU  - Badros,A Z
AU  - Brunner,J L
AU  - Fenton,R G
AU  - Filicko,J
AU  - Grosso,D L
AU  - Hale,G A
AU  - Howard,D S
AU  - Johnson,V P
AU  - Kniska,A
AU  - Marshall,K W
AU  - Mookerjee,B
AU  - Nath,R
AU  - Rapoport,A P
AU  - Sarkodee-Adoo,C
AU  - Takebe,N
AU  - Vesole,D H
AU  - Wagner,J L
AU  - Flomenberg,N
TI  - Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma
SN  - 0268-3369
PY  - 2004///1112
KW  - Adult
KW  - Amifostine
KW  - administration & dosage
KW  - Antineoplastic Agents, Alkylating
KW  - Combined Modality Therapy
KW  - Female
KW  - Hematopoietic Stem Cell Transplantation
KW  - Hodgkin Disease
KW  - therapy
KW  - Humans
KW  - Lymphoma, Non-Hodgkin
KW  - Male
KW  - Melphalan
KW  - Middle Aged
KW  - Radiation-Protective Agents
KW  - Transplantation Conditioning
KW  - methods
KW  - Transplantation, Autologous
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S
UR  - https://doi.org/10.1038/sj.bmt.1704424
ER  -